Sarah Houlton
Dr Sarah Houlton has a PhD in organic synthesis from Imperial College, and has been a science journalist specialising in chemistry-related topics since the early 1990s. Starting at the Journal of the Society of Dyers & Colourists, she then moved to the pharmaceutical industry magazine Manufacturing Chemist, ultimately becoming its editor. She has been freelance since 2001, and covers both science and business, with a particular interest in the pharma & biotech sector and the polyurethane industry, and the occasional foray into topics such as food ingredients and process engineering. She is based in Hertfordshire, UK.
SponsoredTesting of microorganisms for microbial limits testing by membrane filtration
Experts from Sartorius give us their unfiltered view on safety testing for personal care products
- Business
New J&J subsidiary to absorb talc lawsuit liabilities
Firm aims to use bankruptcy protection and a $2bn trust to resolve thousands of cancer claims
- Business
US judge accepts Purdue’s opioid bankruptcy settlement plan
Deal releases $4.3bn to combat addiction, but protects Sackler family from litigation
- Business
Pfizer backs protein degrader drugs with Arvinas deal
$1bn investment to commercialise breast cancer treatment
- Business
Non-animal test for skin sensitisation gets OECD approval
Combination strategy developed by BASF and Givaudan is the first complete replacement for animal testing
- Business
Searching for more sustainable resin materials
Paul Jones of Bitrez is the 2021 Chemistry World Entrepreneur of the Year
- Sponsored
Sustainable safety testing
Unilever has been researching and applying alternatives to animal testing, and working with industry, academia, government scientists and NGOs to usher in a new era of sustainable safety testing that isn’t reliant on animal models.
- Sponsored
A biodegradable future
By investing in research, working with its partners across its supply chain, and considering the entire product lifecycle, Unilever is making a biodegradable future obtainable
- Business
Pharmaceuticals roundup 2020
Alongside the race for Covid-19 treatments and vaccines, the industry has maintained momentum
- Business
AstraZeneca to buy rare disease drugmaker Alexion in $39bn deal
Transaction would be the largest in AstraZeneca’s history
- Research
How to solve a ‘nasty’ compound’s structure with a million-Euro synchrotron
Chemists overcomes challenges of handling explosive and toxic nitrogen to investigate its structure using Germany’s most expensive x-ray source
- Business
Covid-19 highlights need to update pharma supply chains
Resilience and redundancy are key amid protectionist calls for domestic manufacturing
- Business
This little Crispr went to market
Gene editing technology heading towards commercial reality in pharmaceuticals, food and organ transplant
- Business
Cancer and rare diseases dominated 2019 drug approvals
More streamlined review processes and changing R&D priorities have contributed to sustained increase in new medicines
- Business
Pharmaceuticals roundup 2019
Under the shadow of political turmoil and major lawsuits, the industry returned to its strengths – making new drugs, and finding new ways to do it better
- Business
Sixth in a line of Alzheimer’s drugs fails in trials
Treatments designed to stop amyloid peptide formation all seem to cause cognitive impairment rather than prevent it
- Business
Landmark ruling in Oklahoma opioid lawsuit
J&J judged responsible for ‘public nuisance’ in first case to go to trial
- Business
Enhancing solvents' sustainability
Increased recycling and replacing toxic solvents with greener alternatives will reduce environmental impact
- Business
Curbing industry’s carbon emissions
Replacing fossil-fuelled furnaces with renewable electrical heating and cutting carbon from some heavy industries could make a serious dent in climate targets
- Business
AbbVie to acquire Allergan in multibillion-dollar merger
Takeover deal will create world’s fifth-largest pharma company
